Circassia Pharmaceuticals (CIR)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

17.00p
   
  • Change Today:
      0.18p
  • 52 Week High: 66.00
  • 52 Week Low: 14.40
  • Currency: UK Pounds
  • Shares Issued: 375.18m
  • Volume: 1,351,317
  • Market Cap: 63.78m
  • RiskGrade: 7
  • Beta: 0.54

CIR Overview

Circassia is a specialty biopharmaceutical company focused on the development and commercialisation of a range of immunotherapy product candidates for the treatment of allergy.

1 Day Chart (23-10-2019)

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -83.6% -52.8%
ROCE 47.0%  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 1.3 1.0
Pr/Book 0.5  
Latest F'cast
Revenue 4.3% 27.7%
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

CIR Fundamentals

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-14 n/a (44.00) (21.00)p n/a n/a n/a n/a 0.0%
31-Dec-15 10.80 (62.80) (20.00)p n/a n/a n/a n/a 0.0%
31-Dec-16 23.10 (38.80) (13.00)p n/a n/a n/a n/a 0.0%
31-Dec-17 46.30 (74.20) (19.00)p n/a n/a n/a n/a 0.0%
31-Dec-18 48.30 (55.80) (14.00)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

CIR Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 61.67 (32.55) (8.63)p n/a n/a n/a n/a 0.0%
31-Dec-20 80.32 (9.95) (3.57)p n/a n/a n/a n/a 0.0%

Copyright © 2019 FactSet Research Systems Inc. All rights reserved.

CIR Company Announcements

US launch of Duaklir at CHEST 2019 21-Oct-2019 07:00 RNS
Grant of options 17-Oct-2019 17:34 RNS
Holding(s) in Company 04-Oct-2019 16:30 RNS

Latest CIR Director Deals

Traded Action Notifier PriceAmountValue
30-Sep-19 Buy Jonathan Emms 16.52p 300,000 49,544.10

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

CIR Market Data

Currency UK Pounds
Share Price 17.00p
Change Today 0.18p
% Change 1.04 %
52 Week High 66.00
52 Week Low 14.40
Volume 1,351,317
Shares Issued 375.18m
Market Cap 63.78m
Beta 0.54
RiskGrade 7

CIR Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
54.72% above the market average54.72% above the market average54.72% above the market average54.72% above the market average54.72% above the market average
89.66% above the sector average89.66% above the sector average89.66% above the sector average89.66% above the sector average89.66% above the sector average
Price Trend
91.89% below the market average91.89% below the market average91.89% below the market average91.89% below the market average91.89% below the market average
83.05% below the sector average83.05% below the sector average83.05% below the sector average83.05% below the sector average83.05% below the sector average
Income Not Available
Growth
31.57% above the market average31.57% above the market average31.57% above the market average31.57% above the market average31.57% above the market average
18.92% above the sector average18.92% above the sector average18.92% above the sector average18.92% above the sector average18.92% above the sector average

What The Brokers Say

Strong Buy 2
Buy 0
Neutral 0
Sell 0
Strong Sell 1
Total 3
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

CIR Dividends

No dividends found

Trades for 23-Oct-2019

Time Volume / Share Price
16:35 27,080 @ 17.00p
16:29 1,957 @ 17.00p
16:29 6,659 @ 17.00p
16:29 1,682 @ 17.00p
16:29 6,303 @ 17.00p

CIR Key Personnel

Chair Francesco Granata
CEO Steven Harris
CFO Julien Cotta

Top of Page